Study Title

Phase I Dose Escalation Study to Evaluate Tolerability and Safety of 225Ac-PSMA I&T in Patients With Metastatic Prostate Cancer

Study Details

Description:

225Ac-PSMA I&T is a radiopharmaceutical for therapy of prostate cancer. PSMA is overexpressed on prostate cancer cells. Actium-225 is an alpha emitting radionuclide. When PSMA I&T is labelled with Actium-225, it can be applied as therapy for prostate cancer.

Sponsor:

Erasmus Medical Center

Contacts:

Sui wai Ling

s.ling@erasmusmc.nl

+31107033612

Laurens Groenendijk

imaging.trialbureau@erasmusmc.nl

+31107033612

Government Study Link:

NCT05902247 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468